Publications

Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe

Authors: Asboe D, Bansi L, Camacho R, Codoñer FM, De Luca A, Di Giambenedetto S, Dunn D, Fanti I, Ghisetti V, Kaiser R, Prosperi MCF, Sönnerborg A, Torti C, van de Vijver DC, Van Laethem K, Vandamme AM, Zazzi M
Publication Year: 2013
Journal: Journal of Infectious Diseases
Link: http://jid.oxfordjournals.org/content/early/2013/01/11/infdis.jit017.abstract

HIV-1 drug resistance represents a major obstacle to infection and disease control. This retrospective study analyzes trends and determinants of resistance in antiretroviral treatment (ART)-exposed individuals across 7 countries in Europe. Of 20,323 cases, 80% carried at least one resistance mutation: these declined from 81% in 1997 to 71% in 2008. Predicted extensive 3-class resistance was rare (3.2% considering the cumulative genotype) and peaked at 4.5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis.
Read More

HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure

Authors: Beheydt G, Bruzzone B, Camacho RJ, De Luca A, Deforche K, Grossman Z, Imbrechts S, Incardona F, Libin P, Pironti A, Rhee SY, Ruiz L, Sangeda RZ, Shafer RW, Sönnerborg A, Theys K, Torti C, Van de Vijver DA, Van Laethem K, Van Wijngaerden E, Vandamme AM, Vercauteren J, Zazzi M
Journal: Infection Genetics and Evolution
Link: http://www.ncbi.nlm.nih.gov/pubmed/23523594

We previously modeled the in vivo evolution of human immunodeficiency virus-1 (HIV-1) under drug selective pressure from cross-sectional viral sequences. These fitness landscapes (FLs) were made by using first a Bayesian network (BN) to map epistatic substitutions, followed by scaling the fitness landscape based on an HIV evolution simulator trying to evolve the sequences from treatment naïve patients into sequences from patients failing treatment.
Read More

Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study).

OBJECTIVES:
The EuResist expert system is a novel data-driven online system for computing the probability of 8-week success for any given pair of HIV-1 genotype and combination antiretroviral therapy regimen plus optional patient information. The objective of this study was to compare the EuResist system vs. human experts (EVE) for the ability to predict response to treatment.
Read More

European Recommendations for the Clinical Use of HIV Drug Resistance Testing: 2011 Update.

Authors: Ceccherini-Silberstein F, De Luca A, European HIV Drug Resistance Guidelines Panel, Palmisano L, Paraskevis D, Paredes R, Poljak M, Schmit JC, Sönnerborg A, Soriano V, Walter H, Camacho RJ, Vandamme AM
Journal: AIDS Reviews
Link: https://apps.webofknowledge.com/full_record.do?product=UA&search_mode=GeneralSearch&qid=19&SID=Y2ytOr2frNCuRlReLtM&page=1&doc=1

The European HIV Drug Resistance Guidelines Panel, established to make recommendations to clinicians and virologists, felt that sufficient new information has become available to warrant an update of its recommendations, explained in both pocket guidelines and this full paper.
Read More

Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients.

BACKGROUND:
The effect of drug resistance transmission on disease progression in the newly infected patient is not well understood. Major drug resistance mutations severely impair viral fitness in a drug free environment, and therefore are expected to revert quickly. Compensatory mutations, often already polymorphic in wild-type viruses, do not tend to revert after transmission.
Read More

Publications

Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe

HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure

Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study).

European Recommendations for the Clinical Use of HIV Drug Resistance Testing: 2011 Update.

Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients.

About GHTM

Contacts

Map